HLB's Elevar Participates in European Oncology Congress, Engages with Global Healthcare Professionals
HLB's U.S. subsidiary, Elevar Therapeutics, participated in the European Society for Medical Oncology (ESMO 2026) congress.
According to HLB on October 27, this was Elevar's first appearance at a globally renowned cancer congress since the U.S. Food and Drug Administration (FDA) approved LYRFIGTU. ESMO brings together tens of thousands of oncology experts and pharmaceutical and biotech industry representatives from around the world to discuss the latest research findings and clinical strategies in cancer treatment.
Elevar set up its own booth in the exhibition area and divided the space into commercial, medical, and scientific sections. In the commercial section, it engaged with key stakeholders regarding preparations for the U.S. launch of LYRFIGTU following FDA approval. In the medical and scientific sections, it discussed clinical data and ongoing research and development plans with healthcare professionals. In addition to operating the booth, Elevar met with leading experts to hear their views on the clinical use of LYRFIGTU ahead of its entry into the U.S. market and on the treatment landscape for cholangiocarcinoma.
Research findings related to Elevar's key pipeline assets were also presented at the congress. Additional follow-up results from the investigator-initiated Phase 2 trial 'THRIVE (KCSG LU23-09)' of rivoceranib in patients with previously treated metastatic thymic epithelial tumors (TET) were presented as a Rapid Oral Presentation. At a median follow-up of 13.6 months, the objective response rate (ORR) was 35% and the disease control rate (DCR) was 85% across all patients, while median progression-free survival (mPFS) was 11.8 months.
Hot Picks Today
"They're Coming After My Pension Too?" Public Unease Mounts... Spain Sees Mass Protest Over Reform Push
- "A Really Beautiful Butt"... How Did Nicki Minaj React to Trump's Unexpected Remark?
- [Breaking] 18-Month Prison Sentence Finalized for Kang Ui-gu, Former Annex Office Chief, over "After-the-Fact Martial Law Proclamation"
- "Why Is That Woman Acting Like That?" Wailing and Lying Down... A Disturbance in the Middle of Gangnam-daero
- "Stockpile 9 Liters of Bottled Water and Three Days' Worth of Food"... UK on Edge as Nationwide Emergency Preparedness Alert Issued
"We are preparing for the U.S. launch following FDA approval of LYRFIGTU," said Kim Donggeon, CEO of Elevar Therapeutics. "Our participation in ESMO provided an opportunity for scientific exchange with healthcare professionals and industry representatives, and we will continue additional research and regulatory activities outside the United States."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
